JERUSALEM--(BUSINESS WIRE)--July 12, 2006--Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA - News) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company’s Abbreviated New Drug Application (ANDA) to market its generic version of Novartis’ hypertension treatment Lotrel (Amlodipine Besylate and Benazepril HCl) Capsules, 2.5 mg base/10 mg, 5 mg base/10 mg, 5 mg base/20 mg, and 10 mg base/20 mg.
